AB Science: ODS designation for masitinib in Switzerland – 12/28/2022 at 08:45


(CercleFinance.com) – AB Science announces that its masitinib has received orphan drug designation (ODS) from the Swiss Institute for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS).

This designation offers the sponsor a series of incentives, including the possibility of benefiting from a simplified authorization procedure by Swissmedic, a waiver of fees and an extended document protection period of 15 years.

It is granted to products developed to treat a fatal or chronically disabling disease affecting no more than five people out of 10,000 in Switzerland, or whose active substance has been recognized for rare diseases in another country.



Source link -86